Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles
Open Access
- 1 January 2003
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 18 (1) , 45-49
- https://doi.org/10.1093/humrep/deg021
Abstract
BACKGROUND: The introduction of GnRH antagonists such as cetrorelix acetate has made possible the simplification of ovarian stimulation. However, the most effective protocol for their administration has not yet been clearly defined. METHODS: Forty women with male‐factor infertility undergoing 40 ICSI cycles were included in the study. Clomiphene citrate at 100 mg a day was given from cycle day 3 through day 7. hMG at 150 IU was given on cycle days 4, 6 and 8, and was adjusted from day 9 according to the follicular and hormone responses. Cetrorelix acetate at 2.5 mg was administered when the leading follicle reached 14 mm. The remaining 0.5 mg was divided into two 0.25 mg injections for possible later use. Serum FSH, LH, estradiol and progesterone levels were measured daily from the day of cetrorelix acetate injection until hCG was given. RESULTS: Serum LH level was suppressed effectively for 4 days. Four patients (10%) needed one or two additional injections of 0.25 mg cetrorelix acetate. No premature LH surge was detected in any of the women treated. Sixteen women became pregnant (40%), of which 14 pregnancies (35%) were ongoing at the time of writing. CONCLUSIONS: This study demonstrates that this new protocol is feasible for couples with male‐factor infertility undergoing ICSI.Keywords
This publication has 10 references indexed in Scilit:
- GnRH antagonist in assisted reproduction: a Cochrane reviewHuman Reproduction, 2002
- Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonistFertility and Sterility, 2002
- Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor respondersEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2001
- Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulationHuman Reproduction, 2001
- Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelinHuman Reproduction, 2000
- Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)Fertility and Sterility, 2000
- Will GnRH antagonists provide new hope for patients considered `difficult responders' to GnRH agonist protocols?Human Reproduction, 1999
- The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mgHuman Reproduction, 1998
- Comparison of human menopausal gonadotropin, clomiphene citrate, and combined human menopausal gonadotropin-clomiphene citrate stimulation protocols for in vitro fertilizationFertility and Sterility, 1986
- In vitro fertilization management and results in stimulated cycles with spontaneous luteinizing hormone dischargeFertility and Sterility, 1986